These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28790118)

  • 21. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor Regression and Cure Depends on Sustained Th1 Responses.
    Dai M; Hellstrom I; Yip YY; Sjögren HO; Hellstrom KE
    J Immunother; 2018 Oct; 41(8):369-378. PubMed ID: 29912725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.
    Grivas P; Drakaki A; Friedlander TW; Sonpavde G
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():284-300. PubMed ID: 31099684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
    Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
    Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
    Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
    BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination Strategies PD-1/PD-L1 Antagonists.
    Sznol M
    Cancer J; 2018; 24(1):54-57. PubMed ID: 29360729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases.
    Knackstedt R; Sussman TA; McCahon L; Song JM; Funchain P; Gastman B
    Ann Oncol; 2019 Aug; 30(8):1399-1400. PubMed ID: 31250007
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.
    Kelly K; Infante JR; Taylor MH; Patel MR; Wong DJ; Iannotti N; Mehnert JM; Loos AH; Koch H; Speit I; Gulley JL
    Cancer; 2018 May; 124(9):2010-2017. PubMed ID: 29469949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy?
    Saleh K; Khalifeh-Saleh N; Kourie HR; Nasr F; Chahine G
    Immunotherapy; 2018 Mar; 10(3):163-165. PubMed ID: 29370724
    [No Abstract]   [Full Text] [Related]  

  • 30. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
    J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
    Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
    Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?
    Simmet V; Eberst L; Marabelle A; Cassier PA
    Ann Oncol; 2019 Nov; 30(11):1751-1759. PubMed ID: 31435659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response.
    Hellstrom KE; Dai M; Hellstrom I
    Hum Antibodies; 2017; 25(3-4):147-153. PubMed ID: 28085017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
    Dada R
    Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis.
    Santoni M; Conti A; Buti S; Bersanelli M; Foghini L; Piva F; Giulietti M; Lusuardi L; Battelli N
    Immunotherapy; 2018 Nov; 10(15):1303-1313. PubMed ID: 30474475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
    Zhan MM; Hu XQ; Liu XX; Ruan BF; Xu J; Liao C
    Drug Discov Today; 2016 Jun; 21(6):1027-36. PubMed ID: 27094104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.
    Dai M; Yip YY; Hellstrom I; Hellstrom KE
    Clin Cancer Res; 2015 Mar; 21(5):1127-38. PubMed ID: 25142145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
    Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
    Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.